Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients

Keyphrases

• Hemodialysis 100%
• End-stage Renal Disease Patients 100%
• N-acetylcysteine 100%
• Asymmetric Dimethylarginine 100%
• Dimethylarginine Dimethylaminohydrolase 20%
• Treatment Group 10%
• Antioxidant Effect 10%
• Paired T-test 10%
• Independent T-test 10%
• Cardiovascular Disease 10%
• Am(III) 10%
• Cardiovascular Risk 10%
• Placebo 10%
• Diabetic Patients 10%
• Risk of Death 10%
• End-stage Renal Disease 10%
• Pulse Pressure 10%
• Per Se 10%
• Chronic Kidney Disease Patients 10%
• Causes of Mortality 10%
• Hemodynamic Parameters 10%
• Pro-oxidant 10%
• Intravenous Infusion 10%
• Reactive Oxidant Species 10%
• Dialysis Patients 10%
• Direct Antioxidants 10%
• Pre-dialysis 10%
• Uremic Patients 10%
• Indirect Antioxidants 10%
• Thiol Compounds 10%

Pharmacology, Toxicology and Pharmaceutical Science

• End Stage Renal Disease 100%
• Hemodialysis 100%
• Acetylcysteine 100%
• 6 N,n' Dimethylarginine 100%
• N(g),n(g) Dimethylarginine 100%
• Oxidizing Agent 20%
• Dimethylargininase 20%
• Diabetes Mellitus 10%
• Antioxidant 10%
• Bioavailability 10%
• Placebo 10%
• Chronic Kidney Failure 10%
• Cardiovascular Disease 10%
• Thiol 10%
• Treatment Group 10%